T

he Australian consumer watchdog agency is taking Novartis (NVS) and GlaxoSmithKline (GSK) to court for allegedly false or misleading marketing about a pair of gels used to treat pain.

The move is the latest by the Australian Competition and Consumer Commission to crack down on drug makers for making “misleading representations” about their products. Last year, the agency fined Reckitt Benckiser $4.5 million for deceptive practices in promoting a pain medication.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • If fading memory serves, Voltaren was ‘a hot new US product’ for CibaGeigy 30 years ago. A new meaning to ‘evergreening!’

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.